Quoin Pharmaceuticals, Ltd. (QNRX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$4.03

From 52W high−82.15%

Volume15420.00

Market cap$19.12M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$4.03

From 52W high

−82.15%

Volume

15420.00

Market cap

$19.12M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

P/E (TTM)

—

RSI (14)

26.5

MomentumView details →

1D Return

+2.05%

YTD Return

−72.97%

SummaryUpdated Jun 1, 2026

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) is a specialty pharmaceutical company founded in 2016 and based in Ashburn, Virginia. The company focuses exclusively on developing therapeutic products for rare and orphan diseases, particularly rare skin conditions that affect small patient populations with significant unmet medical needs. Since its initial public offering in August 2016, Quoin has concentrated its efforts on advancing a pipeline of topical treatments through clinical development, with its lead candidate targeting Netherton Syndrome, an extremely rare genetic skin disorder.

Ask drillr about Quoin Pharmaceuticals, Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

4.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−476.97%

ROA (TTM)

−156.71%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+94.26%

FCF YoY

−43.87%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+99.55%

EBITDA YoY

−53.00%

MomentumView details →

1D Return

+2.05%

YTD Return

−72.97%

1Y Return

−76.16%

RSI (14)

26.5

vs 50D SMA

−30.85%

vs 200D SMA

−39.46%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.76x

Quick Ratio

1.76x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.90

EPS Surprise

−3.83%

Beats (12Q)

4/12

Next Q EPS Est

−$1.49

Avg Surprise (4Q)

−34.55%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−18.76M

Op. CF (TTM)

−15.39M

Next earningsNov 5, 2026 →

Latest newsMore news →

Quoin Pharmaceuticals announced that a peer-reviewed paper introducing QRX003 and its mechanism of action in Netherton syndrome was accepted for publication in Dermatology and Therapy.14d ago

The U.S. Food and Drug Administration granted Rare Pediatric Disease designation to Quoin Pharmaceuticals' QRX003 for the treatment of Peeling Skin Syndrome, the second such designation for the drug after a prior one for Netherton Syndrome.42d ago

Similar companies

VYNE Therapeutics Inc.VYNE Sensei Biotherapeutics, Inc.SNSE OmniAb, Inc.OABIW Fractyl Health, Inc. Common StockGUTS Marker Therapeutics, Inc.MRKR Cocrystal Pharma, Inc.COCP Find similar companies →

Latest newsMore news →

Quoin Pharmaceuticals announced that a peer-reviewed paper introducing QRX003 and its mechanism of action in Netherton syndrome was accepted for publication in Dermatology and Therapy.14d ago The U.S. Food and Drug Administration granted Rare Pediatric Disease designation to Quoin Pharmaceuticals' QRX003 for the treatment of Peeling Skin Syndrome, the second such designation for the drug after a prior one for Netherton Syndrome.42d ago Quoin Pharmaceuticals announced positive clinical trial results for its product on Friday morning.53d ago